GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NexImmune Inc (NAS:NEXI) » Definitions » Shiller PE Ratio

NexImmune (NexImmune) Shiller PE Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NexImmune Shiller PE Ratio?

NexImmune does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


NexImmune Shiller PE Ratio Historical Data

The historical data trend for NexImmune's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexImmune Shiller PE Ratio Chart

NexImmune Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial - - - - -

NexImmune Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NexImmune's Shiller PE Ratio

For the Biotechnology subindustry, NexImmune's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NexImmune's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NexImmune's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where NexImmune's Shiller PE Ratio falls into.



NexImmune Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

NexImmune does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.


NexImmune  (NAS:NEXI) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


NexImmune Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of NexImmune's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NexImmune (NexImmune) Business Description

Traded in Other Exchanges
N/A
Address
9119 Gaither Road, Gaithersburg, MD, USA, 20877
NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
Executives
Alan S. Roemer director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Timothy Stover officer: VP, Corporate Controller C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Zhengbin Yao director 10301 STELLA LINK ROAD, HOUSTON TX 77025
Leena Gandhi director C/O NEXIMMUNE, 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Timothy Bertram director C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Paul D'angio director C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Grant Verstandig director C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Mathias Oelke officer: Chief Science Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Kristi Jones officer: Chief Operating Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Jerome B Zeldis officer: EVP of R&D 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Scott Carmer director, officer: President and CEO C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
John Trainer officer: Chief Financial Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Robert Douglas Knight officer: Chief Medical Officer C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877

NexImmune (NexImmune) Headlines

From GuruFocus